Vaping preferences of individuals who vaporise dry herb cannabis, cannabis liquids and cannabis concentrates

Morgan, Jody; Gschwend, Grace; Houston, Matilda; Jones, Alison L; Kelso, Céline

doi:10.1016/j.drugalcdep.2022.109632

Cited by 7 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this sample, puff duration was approximately 4 s on average. This duration is greater than previous topographical examinations of cannabis cigarette smoking which revealed an average puff duration of 1.3 s (McClure et al, 2012), but more closely reflect previous survey work finding respondents estimated their cannabis oil vaporization puff duration to be 5.1 s on average (Morgan et al, 2022). This self-report accuracy of consumption contradicts previous pilot work utilizing an electronic nicotine delivery system where the device recorded twice as many puffs, or “hits,” as participants reported taking through EMA (Li et al, 2021).…”

Section: Discussionsupporting

confidence: 74%

“…These findings are consistent with online survey data ( N = 557) spanning across 24 countries which found that individuals who vape were predominantly young (<35 years) and male (Morgan et al, 2022). Approximately half (49.1%) of their sample reported both medicinal and recreational use, and an additional 13.5% reported vaporizing cannabis for medicinal purposes only (Morgan et al, 2022). Notably, individuals under the age of 18 were excluded from participation in that study.…”

supporting

confidence: 90%

“…Demographics for those who have vaped show that those individuals are approximately 29 years old on average and primarily Caucasian (63.4%) males (63.4%; Lee et al, 2016). These findings are consistent with online survey data ( N = 557) spanning across 24 countries which found that individuals who vape were predominantly young (<35 years) and male (Morgan et al, 2022). Approximately half (49.1%) of their sample reported both medicinal and recreational use, and an additional 13.5% reported vaporizing cannabis for medicinal purposes only (Morgan et al, 2022).…”

supporting

confidence: 90%

“…Interpretations of these findings should be limited to suggestions for feasible future work utilizing a naturalistic design. That said, sample demographics appear to broadly represent individuals who vape cannabis for medicinal purposes (Cranford et al, 2016; Lee et al, 2016; Morgan et al, 2022). Exact age at time of participation was not determined.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

A preliminary characterization of cannabis oil use and vaporization among individuals who use for medical purposes: A pilot study.

Smith,

Aston,

Farris

2024

Experimental and Clinical Psychopharmacology

View full text Add to dashboard Cite

Little is known about the naturalistic use of cannabis oil vaporization, a high-potency product with the ability to be administered discreetly. This pilot study evaluated the feasibility of utilizing a "smart" vaporizer and application to assess the timing, frequency, socioenvironmental factors, and substance use involved in cannabis oil vaporization. Adults with a medical cannabis registration card were recruited from a dispensary in Rhode Island and completed a 2-week study monitoring period using the Gram1 vaporizer, followed by a poststudy qualitative interview. The sample included nine adults who were predominantly male (89%), 100% White, and 100% non-Hispanic. The Gram1 collected topographical vaping data, and the cellphone application utilized ecological momentary assessment (EMA) to assess socioenvironmental factors and other substance use. Qualitative interview data were coded, and illustrative quotations were selected to support quantitative findings. A total of 224 vaping sessions were recorded reflecting 76.4% of the study monitoring period. There was an average of 1.79 vaping sessions per day across all days. Participants took 8.76 puffs on average (SD = 8.23) per vaping session, and the session lasted 2.59 min on average (SD = 4.19). Regular vaporization was exhibited across days of the week and hours of the day. EMA reports indicated that smoking cannabis flower was the most common additional mode of cannabis administration. This study utilized a naturalistic design with novel topographical data and EMA to characterize cannabis oil vaporization. These findings establish the feasibility of collecting objective, momentary data to better understand use behaviors which are critical to informing safe consumption. Public Health SignificanceThis pilot study demonstrates that there are feasible ways of measuring cannabis oil vaporization and related factors in real-time. Assessment of naturalistic cannabis oil vaporization is especially critical because it is a high-potency product with the ability to be administered discreetly. Preliminary findings indicate consistent use across days of the week and distinctive patterns of use throughout the day.

show abstract

Section: Discussionsupporting

confidence: 74%

supporting

confidence: 90%

supporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

A preliminary characterization of cannabis oil use and vaporization among individuals who use for medical purposes: A pilot study.

Smith,

Aston,

Farris

2024

Experimental and Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Based on the average size of cartridge and duration of use, average daily consumption was estimated to be 56 mg per day in Canada and 64 mg per day in the U.S. [82]. A small subpopulation of cannabis concentrate users (N = 83 of 577 surveyed) from a cannabis vaporization survey of consumers from the U.S., the European Union, Australia, and New Zealand self-reported an average of 4600 ± 7000 mg cannabis concentrate use per month [83]. Considering the high degree of error, small sample size, and self-report nature of the study, the resultant data was given low weight for H&P determination.…”

Section: Exposure Assessmentmentioning

confidence: 99%

A First-Tier Framework for Assessing Toxicological Risk from Vaporized Cannabis Concentrates

Vreeke

Faulkner

Strongin

et al. 2022

Toxics

View full text Add to dashboard Cite

Vaporization is an increasingly prevalent means to consume cannabis, but there is little guidance for manufacturers or regulators to evaluate additive safety. This paper presents a first-tier framework for regulators and cannabis manufacturers without significant toxicological expertise to conduct risk assessments and prioritize additives in cannabis concentrates for acceptance, elimination, or further evaluation. Cannabinoids and contaminants (e.g., solvents, pesticides, etc.) are excluded from this framework because of the complexity involved in their assessment; theirs would not be a first-tier toxicological assessment. Further, several U.S. state regulators have provided guidance for major cannabinoids and contaminants. Toxicological risk assessment of cannabis concentrate additives, like other types of risk assessment, includes hazard assessment, dose–response, exposure assessment, and risk characterization steps. Scarce consumption data has made exposure assessment of cannabis concentrates difficult and variable. Previously unpublished consumption data collected from over 54,000 smart vaporization devices show that 50th and 95th percentile users consume 5 and 57 mg per day on average, respectively. Based on these and published data, we propose assuming 100 mg per day cannabis concentrate consumption for first-tier risk assessment purposes. Herein, we provide regulators, cannabis manufacturers, and consumers a preliminary methodology to evaluate the health risks of cannabis concentrate additives.

show abstract

Clinical application and future consideration and potential of cannabis

Dhiman,

Mittal,

Tushir

2024

Cannabis and Derivatives

View full text Add to dashboard Cite

Vaping preferences of individuals who vaporise dry herb cannabis, cannabis liquids and cannabis concentrates

Cited by 7 publications

References 19 publications

A preliminary characterization of cannabis oil use and vaporization among individuals who use for medical purposes: A pilot study.

A preliminary characterization of cannabis oil use and vaporization among individuals who use for medical purposes: A pilot study.

A First-Tier Framework for Assessing Toxicological Risk from Vaporized Cannabis Concentrates

Clinical application and future consideration and potential of cannabis

Contact Info

Product

Resources

About